Proactive Investors - Run By Investors For Investors

Canntab Therapeutics reports record share price highs in wake of corporate advances

Shares in Canntab surged this week after the company unveiled positive test results on its oral extended release formulation
medical cannabis
The firm's shares reached an all-time daily high and closing prices of C$1.74 and C$1.41, respectively, Wednesday

Pot pill developer Canntab Therapeutics Limited (CSE:PILL) pointed out the highs reached by its share price Wednesday in the wake of news announcements.

In a release Thursday, the firm said its shares had reached a new all-time daily high and closing prices of C$1.74 and C$1.41, respectively, on the Canadian Securities Exchange (CSE).

The company also traded an aggregate of 1.6mln shares Wednesday at a value of C$2.06mln, which represents its all-time high daily volume and surpasses its previous high set on its first day of public trading on April 20.

“We are thrilled that the investment community is taking notice of the positive developments occurring at Canntab,” said Canntab CEO Jeff Renwick in a statement.

Shares in Canntab surged this week after the company unveiled positive test results on its oral extended release formulation.

Read: Canntab Therapeutics shares reach all-time highs amid flurry of announcements

The firm said it would now begin manufacturing batches of these tablets for pharmacokinetic and clinical testing.

The testing was a collaboration with medical cannabis producer Emblem Crop (CVE:EMC, OTCQX:EMMBF) and showed that the pills released cannabinoids consistently over a 12-hour period.

Also this week, Canntab's plans to provide pot pills to patients and doctors in Canada were further advanced, as the company struck a definitive collaboration and profit sharing agreement with FSD Pharma.

As previously reported, the latter will help the firm to obtain a license to process and sell cannabis products and will provide it with up to 10,000 square feet at its facility, which lies one hour east of Toronto in Cobourg, Ontario.

Based in Markham, Ontario, Canntab is engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended or sustained release pharmaceutical dosages for therapeutic use.

Canntab shares jumped 17.7% to C$1.66 in Thursday’s afternoon session.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full PILL profile View Profile

Canntab Therapeutics Ltd Timeline

Related Articles

cannabis leaf
May 08 2019
The company plans to leverage its portfolio of brands as well as its distribution network of more than 39,000 European pharmacies to maximize margins and profitability
A cannabis plant shown next to an oil-based product
April 23 2019
THC is executing a medicinal cannabis strategy in Australia, New Zealand and Canada and is looking to Asian markets.
cannabis bud on tray
April 25 2019
Armed with a new partnership with Canada's largest pharmacy and an international cultivator, Flowr is aiming to provide medicinal and recreational consumers around the world with premium, high-quality cannabis
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use